SwanBio Therapeutics, a gene therapy company, has named Steven Zelenkofske, DO, MS as its new chief medical officer, it was reported on Monday.
Dr Zelenkofske has over 20 years of experience. Prior to joining SwanBio Therapeutics, he served as the CMO at Achillion Pharmaceuticals and at UniQure. He has held leadership positions at Regado Biosciences, Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. His work includes various therapeutic areas including neurology, immunology, haematology, cardiovascular, metabolic diseases, diabetes, and nephrology.
Tom Anderson, CEO and director of SwanBio Therapeutics, said, 'We are thrilled to add Steven's expertise to our leadership team. His background complements the extensive talent and experience of our existing management team and will help support our goal of developing gene therapies in neurological diseases that deliver real benefit to patients and their families.'
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment